Hepatitis C in liver transplantation

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C in liver transplantation On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C in liver transplantation

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C in liver transplantation

CDC on Hepatitis C in liver transplantation

Hepatitis C in liver transplantation in the news

Blogs on Hepatitis C in liver transplantation

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C in liver transplantation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

## Recommendations for Diagnosis and Treatment of HCV-Infected Children: AASLD Practice Guidelines 2009[1][edit | edit source]

“  |

1.Treatment of HCV-related disease following liver transplantation should be initiated in appropriate candidates after demonstration of recurrent histologic disease but should be undertaken with caution and under the supervision of a physician experienced in transplantation (Class IIa, Level A).

2. Peginterferon alfa either with or without ribavirin should be the preferred regimen when treating patients with hepatitis C after liver transplantation (Class IIa, Level B).

3. Interferon-based therapy should not be used in recipients of heart, lung, and kidney grafts, except for patients who develop ﬁbrosing cholestatic hepatitis (Class III, Level C).

| ”

|
|

## References[edit | edit source]

1. ↑ Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter `|month=` ignored (help)

Template:WS Template:WH